Characteristics of adult URD UCBT recipients
Characteristic . | Bu/Flu/TBI . | Cy/Flu/TBI . |
|---|---|---|
| No., n | 21 | 22 |
| Median age, y (range) | 49 (22-65) | 49 (24-58) |
| Median weight, kg (range) | 75 (55-109) | 73 (51-119) |
| Median time from diagnosis to transplantation (range) | 661 d (105 d - 8 y) | 575 d (102 d - 7 y) |
| Recipient CMV-positive, n (%) | 9 (43) | 7 (32) |
| Diagnosis | ||
| AML, n (%) | 10 (48) | 8 (36) |
| CR1, high risk,* n | 3 | 2 |
| CR2, n | 4 | 6 |
| Not in remission, n | 3 | 0 |
| MDS, n (%) | 2 (9) | 1 (5) |
| Refractory anemia with excess blasts, n | 2 | 0 |
| CMML, n | 0 | 1 |
| Advanced myelofibrosis, n (%) | 0 | 1 (5) |
| CML, n (%) | 2 (9) | 2 (9) |
| Accelerated/prior auto Tx, n | 1 | 0 |
| Postblast crisis, n | 1 | 2 |
| ALL, n (%) | 0 | 3 (14) |
| CR1 (Ph+), n | 0 | 2 |
| Fifth relapse, n | 0 | 1 |
| Hodgkin disease, n (%) | 2 (9) | 0 |
| Relapsed after auto Tx, n | 1 | 0 |
| Primary refractory, n | 1 | 0 |
| NHL, n (%) | 5 (24) | 6 (27) |
| Relapsed DLC in second PR, n | 3 | 1 |
| At least PR3 or refractory, n | 1 | 4 |
| Mantle cell in PR1, n | 1 | 1 |
| Plasma cell leukemia, n (%) | 0 | 1 (5) |
| Indication for reduced-intensity conditioning | ||
| Age at least 45 y, n (%) | 15 (71) | 17 (77) |
| Extensive prior therapy, n (%) | 9 (43); 7 prior auto Tx | 10 (45); 5 prior auto Tx |
| Poor performance status, n (%) | 14 (67) | 10 (45) |
Characteristic . | Bu/Flu/TBI . | Cy/Flu/TBI . |
|---|---|---|
| No., n | 21 | 22 |
| Median age, y (range) | 49 (22-65) | 49 (24-58) |
| Median weight, kg (range) | 75 (55-109) | 73 (51-119) |
| Median time from diagnosis to transplantation (range) | 661 d (105 d - 8 y) | 575 d (102 d - 7 y) |
| Recipient CMV-positive, n (%) | 9 (43) | 7 (32) |
| Diagnosis | ||
| AML, n (%) | 10 (48) | 8 (36) |
| CR1, high risk,* n | 3 | 2 |
| CR2, n | 4 | 6 |
| Not in remission, n | 3 | 0 |
| MDS, n (%) | 2 (9) | 1 (5) |
| Refractory anemia with excess blasts, n | 2 | 0 |
| CMML, n | 0 | 1 |
| Advanced myelofibrosis, n (%) | 0 | 1 (5) |
| CML, n (%) | 2 (9) | 2 (9) |
| Accelerated/prior auto Tx, n | 1 | 0 |
| Postblast crisis, n | 1 | 2 |
| ALL, n (%) | 0 | 3 (14) |
| CR1 (Ph+), n | 0 | 2 |
| Fifth relapse, n | 0 | 1 |
| Hodgkin disease, n (%) | 2 (9) | 0 |
| Relapsed after auto Tx, n | 1 | 0 |
| Primary refractory, n | 1 | 0 |
| NHL, n (%) | 5 (24) | 6 (27) |
| Relapsed DLC in second PR, n | 3 | 1 |
| At least PR3 or refractory, n | 1 | 4 |
| Mantle cell in PR1, n | 1 | 1 |
| Plasma cell leukemia, n (%) | 0 | 1 (5) |
| Indication for reduced-intensity conditioning | ||
| Age at least 45 y, n (%) | 15 (71) | 17 (77) |
| Extensive prior therapy, n (%) | 9 (43); 7 prior auto Tx | 10 (45); 5 prior auto Tx |
| Poor performance status, n (%) | 14 (67) | 10 (45) |
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia; CR, complete remission; MDS, myelodysplasia; CMML, chronic myelo-monocytic leukemia; CML, chronic myelogenous leukemia; auto Tx, autologous transplantation; ALL, acute lymphoblastic leukemia; Ph+, Philadelphia chromosome positive; NHL, non-Hodgkin lymphoma; DLC, diffuse large cell; and PR, partial remission.
AML: CR1 (high-risk) defined by prior myelodysplasia (MDS) or requiring at least 3 induction cycles.